matched UK reference population (p=0.5) (Office of National Statistics). The hospital length of stay was longer in those over 80 (median: 19 vs. 14 days; p=0.001), however, there was no difference in NYHA class, haemodynamics, type of surgical disease, CAMPHOR score or ICU length of stay between the two age groups. There were more concomitant cardiac surgical procedures in the over 80 group (26% vs 11%, p=0.006), although this was not statistically significant when accounting for multiple testing. Conclusions We found similar outcomes in patients under and over 80 years old undergoing PEA, except for a prolonged hospital length of stay in those over 80. Whilst survival is reduced in the over 80 group compared to the under 80, it is no different to the age-sex matched population. Age alone should not be a contraindication for PEA and individuals with suspected CTEPH should be referred for specialist evaluation. 
Introduction COPD exacerbations cause considerable morbidity and mortality. Early identification and appropriate treatment might improve patient outcomes. We sought to determine whether urinary biomarkers are associated with a COPD exacerbation. Method Urine samples from paired stable and exacerbation visits from 55 subjects were available from the COPD-BEAT study. 50 biomarkers were analysed in each sample at Mologic (Mologic LTD). Biomarkers that fulfilled the criteria i) a Abstract P184 Table 1 Baseline and follow-up variables and outcomes subdivided by age cohorts. The follow-up time for NYHA, 6MWT, haemodynamics and CAMPHOR score was 3-6 months. a P-values were calculated using Chi-squared test or Fisher's exact test for categorical data, Wilcoxon rank-sum test for continuous data and Log-rank test for survival data. A Bonferroni adjusted significance threshold of <0.002 was used. Significant P-values are highlighted in bold. Total percentage may not add up to loo due to rounding c Jamieson classification. NYHA, New York Heart Association; 6MWT, 6 minute walking test; mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; Cl, cardiac index; CAMPHOR, Cambridge Pulmonary Hypertension Outcome Review score; IQR, interquartile range; CABG, coronary artery bypass graft; PFO!ASD, patent foramen ovale I atrial septal defect; MVR, mitral valve replacement; AVR, aortic valve replacement; NS, not significant. significant parametric pairwise t-test (p£0.05) and ii) area under the receiver-operator characteristic curve (AUROC !0.59) were selected for inclusion in a logistic regression model. Results The biomarkers that met criteria and were taken forward for further analysis are shown in Table 1 . Of these CC16, CRP, MMP8 and NGAL combined had an AUROC 0.82 (95% confidence interval 0.74 to 0.90). The Youden's index gave a sensitivity and specificity of 78% and 82% respectively. Conclusion COPD exacerbations can be identified by urinary biomarkers. The biomarker panel requires further validation in a prospective longitudinal study. Background There is evidence that acute exacerbations of COPD (AECOPD) may be stratified by peripheral blood eosinophil count and that this may allow identification of a pathologically distinct phenotype with clinical value. We have compared lung function measures between patients with eosinophilic and non-eosinophilic AECOPD. Methods All admissions to an inner London teaching hospital with AECOPD were recorded between 2004 and 2012. The eosinophilic phenotype is defined as a first blood count within 24 hours of admission showing peripheral blood eosinophil count ³ 2% of white blood cells. The first lung function test recorded, performed in a dedicated-laboratory between admissions, were used in analysis. We used non-parametric statistics (Mann-Witney U) for univariate comparisons, and linear regression for multivariate analyses.
Results There were 2793 admissions with AECOPD recorded, we used only first admissions (1, 279 Figure 1 Discussion In this cohort, patients admitted to hospital with acute exacerbations of COPD associated with an eosinophilic phenotype had a higher FEV1 and higher DLCO% predicted. A lower DLCO is more associated with an "emphysematous" than "bronchial" form of COPD. Our Results suggest that the eosinophilic phenotype of AECOPD may be associated with less alveolar and pulmonary capillary damage. Background Patients presenting with an acute exacerbation of COPD (AECOPD) and a peripheral blood eosinophil count!=2% of the total white cell count have a better response to oral cortico-steroids, suggesting that stratification by this biomarker identifies a pathologically distinct phenotype
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